Pasar al contenido principal

MECANISMOS RESPONSABLES DE LA ENFERMEDAD METASTATICA RECURRENTE EN EL CANCER COLORECTAL (RECURRENT_MCRC).

PID2023-153116OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer

  • Centonze, Alessia
  • Novillo-Font, Meritxell
  • Novell, Mireia
  • Martí Renom, Marc A.
  • Batlle Gómez, Eduard
Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945-treated metastases underwent a transition from a poor prognosis-associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell-like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell-like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201., This research has also been funded by ERC advanced grants 884623 (residualCRC), La Caixa Foundation (HR24_00447), Ministerio de Ciencia e Innovación (PID2023-153116OB-I00), Persist_Seq consortium (IMI), La Generalitat de Catalunya (2021 SGR 001278) and CRC STARS (GEACC248909TABE, funded by CRUK-AECC). A. Centonze is supported by EMBO postdoctoral fellowship (ALTF 61-2023). A. Barbachano is supported by CIBERONC. The A. Muñoz laboratory is funded by MICINN (PID22-136729OB-I00). M.A. Marti-Renom and M. Novillo-Font acknowledge support by the Spanish Ministerio de Ciencia e Innovación (PID2023-151484NB-I00 and FPU20/05004, respectively). M.A. Marti-Renom also acknowledges support from Generalitat de Catalunya (2021-SGR-01127).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A plastic EMP1+ to LGR5+ cell state conversion as a bypass to KRASG12D pharmacologic inhibition in metastatic colorectal cancer

  • Centonze, Alessia
  • Novillo-Font, Meritxell
  • Novell, Mireia
  • Martí Renom, Marc A.
  • Batlle Gómez, Eduard
Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945-treated metastases underwent a transition from a poor prognosis-associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell-like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. Significance: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell-like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201., This research has also been funded by ERC advanced grants 884623 (residualCRC), La Caixa Foundation (HR24_00447), Ministerio de Ciencia e Innovación (PID2023-153116OB-I00), Persist_Seq consortium (IMI), La Generalitat de Catalunya (2021 SGR 001278) and CRC STARS (GEACC248909TABE, funded by CRUK-AECC). A. Centonze is supported by EMBO postdoctoral fellowship (ALTF 61-2023). A. Barbachano is supported by CIBERONC. The A. Muñoz laboratory is funded by MICINN (PID22-136729OB-I00). M.A. Marti-Renom and M. Novillo-Font acknowledge support by the Spanish Ministerio de Ciencia e Innovación (PID2023-151484NB-I00 and FPU20/05004, respectively). M.A. Marti-Renom also acknowledges support from Generalitat de Catalunya (2021-SGR-01127).